Clinical trials
Terminated Phase 1 Congenital Abnormalities trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 6 |
| Masonic Cancer Center, University of Minnesota | 2 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2 |
| University of Medicine and Dentistry of New Jersey | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Boston Medical Center | 1 |
| Brigham and Women's Hospital | 1 |
| Bruno C. Medeiros | 1 |
| City of Hope Medical Center | 1 |
| Northwestern University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Congenital Abnormalities | 23 |
| Leukemia, Myeloid, Acute | 19 |
| Leukemia | 10 |
| Leukemia, Erythroblastic, Acute | 10 |
| Leukemia, Monocytic, Acute | 10 |
| Leukemia, Myelomonocytic, Acute | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 |
| Leukemia, Megakaryoblastic, Acute | 9 |
| Blast Crisis | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 7 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.